ZA976167B - Stabilized albumin-free recombinant factor VIII preparation having a low sugar content. - Google Patents

Stabilized albumin-free recombinant factor VIII preparation having a low sugar content.

Info

Publication number
ZA976167B
ZA976167B ZA9706167A ZA976167A ZA976167B ZA 976167 B ZA976167 B ZA 976167B ZA 9706167 A ZA9706167 A ZA 9706167A ZA 976167 A ZA976167 A ZA 976167A ZA 976167 B ZA976167 B ZA 976167B
Authority
ZA
South Africa
Prior art keywords
factor viii
sugar content
low sugar
recombinant factor
viii preparation
Prior art date
Application number
ZA9706167A
Other languages
English (en)
Inventor
Rajiv Nayar
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA976167B publication Critical patent/ZA976167B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA9706167A 1996-07-12 1997-07-11 Stabilized albumin-free recombinant factor VIII preparation having a low sugar content. ZA976167B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/678,492 US5763401A (en) 1996-07-12 1996-07-12 Stabilized albumin-free recombinant factor VIII preparation having a low sugar content

Publications (1)

Publication Number Publication Date
ZA976167B true ZA976167B (en) 1998-02-02

Family

ID=24723010

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9706167A ZA976167B (en) 1996-07-12 1997-07-11 Stabilized albumin-free recombinant factor VIII preparation having a low sugar content.

Country Status (30)

Country Link
US (2) US5763401A (cs)
EP (1) EP0818204B1 (cs)
JP (1) JP4077055B2 (cs)
KR (1) KR100491281B1 (cs)
CN (1) CN1130224C (cs)
AR (1) AR007845A1 (cs)
AT (1) ATE191146T1 (cs)
AU (1) AU718901B2 (cs)
BR (1) BR9704407B1 (cs)
CA (1) CA2210038C (cs)
CO (1) CO4700302A1 (cs)
CZ (1) CZ292183B6 (cs)
DE (1) DE69701548T2 (cs)
DK (1) DK0818204T3 (cs)
ES (1) ES2144293T3 (cs)
GR (1) GR3033669T3 (cs)
HU (1) HU221415B1 (cs)
ID (1) ID19074A (cs)
IL (1) IL121273A (cs)
MY (1) MY125544A (cs)
NZ (1) NZ328297A (cs)
PL (1) PL186950B1 (cs)
PT (1) PT818204E (cs)
RU (1) RU2201252C2 (cs)
SG (1) SG50864A1 (cs)
SK (1) SK282207B6 (cs)
TR (1) TR199700628A2 (cs)
TW (1) TW381027B (cs)
UA (1) UA43882C2 (cs)
ZA (1) ZA976167B (cs)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP1154796B1 (en) * 1999-02-22 2007-06-20 University of Connecticut Novel albumin-free factor viii formulations
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
AU4525801A (en) * 1999-12-30 2001-07-16 Intermune, Inc Gamma-ifn liquid-droplet aerosol and method
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
ATE428439T1 (de) * 2001-12-21 2009-05-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
DE10211227A1 (de) * 2002-03-13 2003-10-02 Aventis Behring Gmbh Verfahren zur Rekonstitution von Iyophilisierten Proteinen
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
PL207018B1 (pl) * 2002-06-21 2010-10-29 Novo Nordisk Helth Care Ag Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
AU2003285075B2 (en) * 2002-10-29 2009-10-29 Durect Corporation Stabilized, solid-state polypeptide particles
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
KR101159559B1 (ko) 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
JP2007505147A (ja) 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
JP2007534633A (ja) * 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤
CA2549593C (en) * 2003-12-19 2014-02-11 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
EP1720519A1 (en) * 2004-03-04 2006-11-15 Wyeth Lyophilization method to improve excipient crystallization
PT2100904E (pt) 2004-04-23 2010-09-24 Conjuchem Biotechnologies Inc Fase sólida para utilização num método para a purificação de conjugados de albumina
EP1750733B1 (en) 2004-05-03 2013-12-11 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
EP2311871A3 (en) * 2004-08-17 2012-08-08 Regeneron Pharmaceuticals, Inc. IL-1 antagonist stable liquid formulation
DK1835938T3 (da) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
CA2600036A1 (en) 2005-03-04 2006-09-14 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
CN101141975B (zh) 2005-03-25 2012-05-23 瑞泽恩制药公司 Vegf拮抗剂制剂
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
BRPI0618893A2 (pt) * 2005-11-22 2011-09-13 Wyeth Corp formulações de proteìna de fusão de imunoglobulina
US20070269863A1 (en) * 2005-12-22 2007-11-22 Bridon Dominique P Process for the production of preformed conjugates of albumin and a therapeutic agent
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
CN103990116A (zh) 2007-04-26 2014-08-20 拜尔健康护理有限责任公司 稳定用于冷冻储藏的重组蛋白液体溶液的方法
MX2009012964A (es) * 2007-06-01 2010-01-14 Acologix Inc Formulacion de peptido estable a alta temperatura.
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
WO2010026186A1 (en) * 2008-09-03 2010-03-11 Octapharma Ag New protecting compositions for recombinantly produced factor viii
RU2540922C2 (ru) 2008-10-30 2015-02-10 Ново Нордиск А/С Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
BRPI0921429B1 (pt) 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
TWI626057B (zh) 2009-06-09 2018-06-11 普龍製藥有限責任公司 血紅素組成物
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
EP2359812A1 (en) 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
DK2635297T3 (da) 2010-11-05 2019-05-06 Baxalta GmbH En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet
CN103282569B (zh) * 2010-12-28 2015-11-25 纳幕尔杜邦公司 由氟化聚酯共混物纱线制得的织物
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN102430116A (zh) * 2011-08-19 2012-05-02 上海新兴医药股份有限公司 用于人凝血因子ⅷ制剂的干热处理方法及其稳定剂
JP2016518321A (ja) * 2013-03-15 2016-06-23 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組み換え因子ｖｉｉｉ配合物
JP6330026B2 (ja) 2013-03-15 2018-05-23 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子ポリペプチド製剤
ES2680942T3 (es) 2013-03-15 2018-09-11 Bayer Healthcare Llc Variante de polipéptidos del factor VIII y procedimientos para su producción y utilización
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
WO2015149144A2 (en) * 2014-04-01 2015-10-08 Advantech Bioscience Farmacêutica Ltda. Stabilization of factor viii without calcium as an excipient
AU2015240353A1 (en) * 2014-04-01 2016-11-17 Advantech Bioscience Farmaceutica Ltda. Stable Factor VIII formulations with low sugar-glycine
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
PL3177317T3 (pl) * 2014-08-04 2020-07-27 Csl Limited Formulacja czynnika viii
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
US20190209475A1 (en) * 2015-11-05 2019-07-11 Novo Nordisk A/S FVIII Formulation
CN106139127B (zh) * 2016-08-05 2020-04-07 无锡药明生物技术股份有限公司 重组凝血因子ⅷ冻干制剂
CN112218883A (zh) 2018-04-26 2021-01-12 艾吉纳斯公司 热休克蛋白结合肽组合物及其使用方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4847362A (en) * 1985-02-01 1989-07-11 New York University Method for purifying antihemophilic factor
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
AU670793B2 (en) * 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
KR100303872B1 (ko) * 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content

Also Published As

Publication number Publication date
MY125544A (en) 2006-08-30
SG50864A1 (en) 1998-07-20
KR980008241A (ko) 1998-04-30
CA2210038A1 (en) 1998-01-12
PL186950B1 (pl) 2004-04-30
PL321058A1 (en) 1998-01-19
EP0818204A3 (en) 1998-02-04
JPH1067679A (ja) 1998-03-10
UA43882C2 (uk) 2002-01-15
EP0818204A2 (en) 1998-01-14
DE69701548T2 (de) 2000-07-27
DK0818204T3 (da) 2000-07-17
ID19074A (id) 1998-06-11
HUP9701191A2 (hu) 1999-06-28
CA2210038C (en) 2007-03-13
GR3033669T3 (en) 2000-10-31
CO4700302A1 (es) 1998-12-29
TW381027B (en) 2000-02-01
CN1130224C (zh) 2003-12-10
AU718901B2 (en) 2000-04-20
KR100491281B1 (ko) 2005-08-05
SK92197A3 (en) 1998-02-04
CZ219497A3 (cs) 1998-01-14
DE69701548D1 (de) 2000-05-04
RU2201252C2 (ru) 2003-03-27
BR9704407B1 (pt) 2010-03-09
SK282207B6 (sk) 2001-12-03
BR9704407A (pt) 2000-06-06
HU9701191D0 (en) 1997-08-28
EP0818204B1 (en) 2000-03-29
IL121273A0 (en) 1998-01-04
HUP9701191A3 (en) 2000-08-28
NZ328297A (en) 1999-09-29
HU221415B1 (en) 2002-09-28
MX9705209A (es) 1998-05-31
ES2144293T3 (es) 2000-06-01
AR007845A1 (es) 1999-11-24
US5763401A (en) 1998-06-09
TR199700628A2 (xx) 1998-01-21
AU2860497A (en) 1998-01-22
IL121273A (en) 2000-09-28
JP4077055B2 (ja) 2008-04-16
CZ292183B6 (cs) 2003-08-13
CN1181974A (zh) 1998-05-20
US5874408A (en) 1999-02-23
ATE191146T1 (de) 2000-04-15
PT818204E (pt) 2000-08-31

Similar Documents

Publication Publication Date Title
ZA976167B (en) Stabilized albumin-free recombinant factor VIII preparation having a low sugar content.
EG24292A (en) Interferon conjugates
ZA975065B (en) Delivery needle.
ZA973193B (en) Beverage stabilization.
ZA989326B (en) A preservative and flavouring system.
IL126474A (en) Diabetic supplement bar
ZA976585B (en) Aprotinin variants having improved properties.
GB9616700D0 (en) Hormone supplement
AU5597998A (en) Recombinant plague vaccine
HK1023426A1 (en) Compressing ideographic characters
IL113725A0 (en) Preparing recombinant aprotini and its variants
GB9612636D0 (en) Flavour modification
GB9612610D0 (en) Easy-to -open envelope
AU710P (en) Royale Boronia megastigma
PL104231U1 (en) Envelope
AU130058S (en) Envelope
ZA965735B (en) Recombinant peptide.
TW326674U (en) Improved seasoning bottle structure (2)
AUPM986994A0 (en) Improvements in levers
ZA978447B (en) Prop.
ZA972805B (en) Prop.
TW300510U (en) Improved folder structure
AUPN908796A0 (en) Thread delivery means
ZA965211B (en) Easy-to-open envelope
PL104759U1 (en) Correspondence envelope